2018 Competitor Analysis Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin - ResearchAndMarkets.com

DUBLIN--()--The "Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin" report has been added to ResearchAndMarkets.com's offering.

Intracellular cancer targets are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy.

The six reports of this package are covering immunotherapeutics against six important intracellular cancer targets:

  • Melanoma-associated antigen A: MAGE-A
  • New York esophageal squamous cell carcinoma-1: NY-ESO-1
  • Human telomerase reverse transcriptase: hTERT
  • Wilms tumor 1: WT1
  • Preferentially expressed antigen in melanoma: PRAME
  • Survivin

This report package includes six Competitor Analysis reports covering immunotherapeutics directed to six different important cancer targets.

The original reports were published in May and June 2018, respectively:

  • Competitor Analysis: MAGE-A-Targeted Immunotherapy
  • Competitor Analysis: NY-ESO-1-Targeted Immunotherapy
  • Competitor Analysis: hTERT-Targeted Immunotherapy
  • Competitor Analysis: WT1-Targeted Immunotherapy
  • Competitor Analysis: PRAME-Targeted Immunotherapy
  • Competitor Analysis: Survivin-Targeted Immunotherapy

Key Topics Covered:

Competitor Analysis: MAGE-A-Targeted Immunotherapy

1. MAGE-A-Targeted Immunotherapy:

  • MAGE-A1
  • MAGE-A3
  • MAGE-A4
  • MAGE-A6
  • MAGE-A10
  • MAGE-A12

2. Corporate & Institutional MAGE-A Immunotherapy R&D Pipelines

Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

1. NY-ESO-1-Targeted Immunotherapy

  • NY-ESO-1 Selective Cancer Vaccines
  • NY-ESO-1 Specific, Multi-Target Cancer Vaccines
  • NY-ESO-1 Selective Adoptive Cell Therapy
  • NY-ESO-1 Specific, Multi-Target Adoptive Cell Therapy
  • NY-ESO-1 Selective Recombinant Antibodies & Proteins

2. Corporate & Institutional NY-ESO-1 Immunotherapy R&D Pipelines

Competitor Analysis: hTERT-Targeted Immunotherapy

1. hTERT-Targeted Immunotherapy

  • hTERT-Selective Cancer Vaccines
  • hTERT-Specific, Multi-Target Cancer Vaccines
  • hTERT-Targeted Adoptive Cell Therapy
  • Other hTERT-Targeted Immunotherapies

2. Corporate & Institutional hTERT Immunotherapy R&D Pipelines

Competitor Analysis: WT1-Targeted Immunotherapy

1. WT1-Targeted Immunotherapy

  • Selective WT1-Targeted Vaccines
  • WT1-Specific, Multi-Target Vaccines
  • WT1-Selective Adoptive Cell Therapy
  • WT1-Specific, Multi-Target Adoptive Cell Therapy
  • WT1-Targeted Antibodies

2. Corporate & Institutional WT1 Immunotherapy R&D Pipelines

Competitor Analysis: PRAME-Targeted Immunotherapy

1. PRAME-Targeted Immunotherapy

  • PRAME-Targeted Selective and Multi-Antigen Cancer Vaccines
  • PRAME-Selective Cellular & Recombinant Immunotherapies
  • PRAME-Specific, Multi-Target Adoptive Cell Therapy

2. Corporate & Institutional PRAME Immunotherapy R&D Pipelines

Competitor Analysis: Survivin-Targeted Immunotherapy

1. Survivin-Targeted Immunotherapy

  • Survivin-Selective Cancer Vaccines
  • Survivin-Specific, Multi-Antigen Cancer Vaccines
  • Survivin-Selective Adoptive T-Cell Therapy & Oncolytic Viral Immunotherapy
  • Survivin-Specific, Multi-Target Adoptive T-Cell Therapy

2. Corporate Survivin Immunotherapy R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/pqjqjh/2018_competitor?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs